<DOC>
	<DOCNO>NCT03017820</DOCNO>
	<brief_summary>This phase I trial study best dose side effect recombinant vesicular stomatitis virus carry human NIS IFN beta gene ( VSV-hIFNbeta-sodium iodide symporter [ NIS ] ) treat patient multiple myeloma , acute myeloid leukemia , T-cell lymphoma come back respond treatment . A virus , call VSV-hIFNbeta-NIS , change certain way , may able kill cancer cell without damage normal cell .</brief_summary>
	<brief_title>VSV-hIFNbeta-NIS Treating Patients With Relapsed Refractory Multiple Myeloma , Acute Myeloid Leukemia , T-cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) VSV-hIFNbeta-NIS patient relapsed/refractory multiple myeloma , acute myeloid leukemia , T-cell lymphoma . SECONDARY OBJECTIVES : I . To determine safety profile VSV-hIFNbeta-NIS . II . To estimate clinical response rate patient relapsed/refractory multiple myeloma , acute myeloid leukemia , T-cell lymphoma overall disease type . III . To estimate progression-free overall survival patient relapsed/refractory multiple myeloma , acute myeloid leukemia , T-cell lymphoma overall disease type . TERTIARY OBJECTIVES : I . To determine time course viral gene expression virus elimination , biodistribution virally infected cell various time point infection VSV-hIFNbeta-NIS use planar single photon emission compute tomography ( SPECT ) /computed tomography ( CT ) imaging . II . To assess virus replication , viremia , viral shed urine respiratory secretion , virus persistence systemic administration VSV-hIFNbeta-NIS . III . To characterize pharmacodynamics ( PD ) VSV-IFNbeta-NIS way measure serum interferon-beta also vesicular stomatitis virus ( VSV ) -real time ( RT ) -polymerase chain reaction ( PCR ) VSV-IFNbeta-NIS . IV . Assess CD8+ T cell ( general VSV-IFNbeta-NIS specific ) natural killer ( NK ) cell response . V. Gene expression analysis pre- post-virotherapy . VI . Assess presence VSV tumor normal tissue subsequent administration intravenous ( IV ) VSV-IFNbeta-NIS . OUTLINE : This dose escalation study . Patients receive VSV-IFNbeta-NIS intravenously ( IV ) 30 minute day 1 , undergo SPECT/CT 3-5 day later . After completion study treatment , patient follow 28 day , every 3 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Relapsed refractory : Multiple myeloma ( MM ) previously treat immunomodulatory drug ( IMID ) , proteosome inhibitor alkylating agent ; OR Oligoblastic acute myeloid leukemia ( AML ) ( = &lt; 30 % blast ) , exclude acute promyelocytic leukemia ( PMLRARA rearrange AMLM3 ) ; either primary refractory relapsed/refractory disease least two front line chemotherapy regimen ( note : induction consolidation chemotherapy consider one line therapy , additionally allogeneic stem cell transplant induction/ consolidation consider additional line therapy ) ; diagnosis base 2008 World Health Organization ( WHO ) criteria ; OR Relapsed Tcell lymphoma ( TCL ) follow type : peripheral Tcell lymphomaNOS ( PTCLNOS ) ; angioimmunoblastic Tcell lymphoma ( AITL ) , anaplastic large cell ( ALCL ) , cutaneous TCL ( CTCL ) mycosis fungoides ( MF ) ; patient fail standard therapy case PTCLNOS , AITL , ALCL either fail ineligible highdose therapy autologous stem cell transplant Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 2 time upper limit normal ( ULN ) Creatinine = &lt; 2.0 mg/dL Direct bilirubin = &lt; 1.5 x ULN International normalize ratio ( INR ) /prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) = &lt; 1.5 x ULN If baseline liver disease , Child Pugh score exceed class A Negative pregnancy test person childbearing potential FOR MULTIPLE MYELOMA ONLY : Measurable disease multiple myeloma define least ONE following : Serum monoclonal protein &gt; = 1.0 g/dL protein electrophoresis &gt; = 200 mg monoclonal protein urine 24hour electrophoresis Serum immunoglobulin free light chain &gt; = 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio FOR MULTIPLE MYELOMA ONLY : Absolute neutrophil count ( ANC ) &gt; = 1000/uL FOR MULTIPLE MYELOMA ONLY : Platelet ( PLT ) &gt; = 100,000/uL FOR MULTIPLE MYELOMA ONLY : Hemoglobin &gt; = 8.5 g/dl FOR AML ONLY : No ANC restriction FOR AML ONLY : PLT &gt; = 10,000/uL ( transfusion get platelet &gt; = 10,000 allow ) FOR AML ONLY : Hemoglobin &gt; = 7.5 g/dl FOR AML ONLY : Absence uncompensated disseminated intravascular coagulation ( DIC diagnose standard International Society Thrombosis Hemostasis [ ISTH ] criterion ) FOR TCL ONLY : ANC &gt; = 1,000/uL FOR TCL ONLY : PLT &gt; = 100,000/uL FOR TCL ONLY : Hemoglobin &gt; = 8.5 g/dl FOR TCL ONLY : Measurable disease CT magnetic resonance imaging ( MRI ) : must least one lesion single diameter &gt; 2 cm tumor cell blood &gt; 5 x10^9/L ; NOTE : skin lesion use area &gt; 2 cm least one diameter photograph ruler image available medical record Absence active central nervous system ( CNS ) involvement ; NOTE : preenrollment lumbar puncture mandatory Ability provide write informed consent Willingness return Mayo Clinic Rochester , Minnesota followup Life expectancy &gt; = 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Willing provide mandatory biological specimen research purpose Availability patient acceptance curative therapy Uncontrolled infection Active tuberculosis hepatitis , history hepatitis B C , chronic hepatitis Any follow prior therapy : Chemotherapy ( IMIDs , alkylating agent , proteosome inhibitor ) = &lt; 2 week prior registration Immunotherapy ( monoclonal antibody ) = &lt; 4 week prior registration Experimental agent case AML TCL within 4 halflives last dose agent New York Heart Association classification III IV , know symptomatic coronary artery disease , symptom coronary artery disease system review , know cardiac arrhythmia ( atrial fibrillation supraventricular tachycardia [ SVT ] ) Active CNS disorder seizure disorder know CNS disease neurologic symptomatology ; case AML active CNS involvement detect lumbar puncture neuroimaging ( do clinically indicate ) Human immunodeficiency virus ( HIV ) positive test result immunodeficiency immunosuppression Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( used nonFood Drug Administration [ FDA ] approve indication context research investigation ) ; NOTE : AML , concurrent use hydroxyurea help control proliferative count allow throughout treatment protocol ; NOTE : TCL , patient may use topical emollient corticosteroid , acetic acid soak , etc . control pruritis prevent infection ; topical chemotherapy allow ( topical nitrogen mustard ) Any follow study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown : Pregnant woman woman reproductive ability unwilling use effective contraception Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 4 week stop treatment Acute promyelocytic leukemia ( AML M3 ) Prior allogeneic bone marrow transplant Multiple myeloma : &gt; = 15 % plasma cell plasmacytoma &gt; 5 cm large diameter TCL : Any mass &gt; = 5 cm AML : current disseminate intravascular coagulopathy ( DIC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>